Key points are not available for this paper at this time.
Lenvatinib reduced tumor PD-L1 level and Treg differentiation to improve anti-PD-1 efficacy by blocking FGFR4. Levels of FGFR4 expression and Treg infiltration in tumor could serve as biomarkers for screening patients with HCC using lenvatinib plus anti-PD-1 combination therapy.
Building similarity graph...
Analyzing shared references across papers
Loading...
Chenhe Yi
Huashan Hospital
Lirong Chen
Jiangnan University
Zhifei Lin
Jiangsu Hengrui Medicine (China)
Hepatology
Fudan University
Huashan Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Yi et al. (Wed,) studied this question.
synapsesocial.com/papers/69df2b39d85e58e37b7a18fe — DOI: https://doi.org/10.1002/hep.31921
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: